drugset / Trial / NCT03715127

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

NCT03715127

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Effects of serotonin 2A/1A receptor stimulation by psilocybin on mood and emotion processing in major depressive disorder: a randomized double-blind placebo-controlled study

Timeline

Start
2019-03-11
Primary completion
2021-10-12
Completion
2022-04-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Psilocybin Other / unclassified 0.215 mg/kg Oral